Sublancin
Sublancin is an antimicrobial peptide, which inhibits DNA replication, transcription and translation, without affecting membrane integrity. Sublancin suppresses glucose uptake for the competition of phosphotransferase system (PTS). Sublancin inhibits B. subtilis strain 168 ΔSPβ with MIC of 0.312 μM.
For research use only. We do not sell to patients.
- CAS No.: 207410-26-2
- Formula: C162H254N50O51S5
- Molecular Weight:3878.38
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
In Vitro
Sublancin (0-500 μM, 24 h) inhibits methicillin-resistant Staphylococcus aureus (MRSA) with MIC of 15 μM, and exhibits no cytotoxicity in RAW246.7 macrophage cells, mouse peritoneal macrophages, and human Caco-2 253 epithelial cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:RAW246.7, Caco-2, P-Mac
-
Concentration:0-500 μM
-
Incubation Time:24 h
-
Result:Maintained cell viability.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Methicillin-resistant Staphylococcus aureus infected mice[1]
-
Dosage:0.5-4 mg/kg
-
Administration:ip, single dose
-
Result:Improved the survival rate, reduced body weight loss.
Chemical Information
-
CAS No. 207410-26-2
-
Molecular Weight 3878.38
-
Formula C162H254N50O51S5
-
Sequence
Gly-Leu-Gly-Lys-Ala-Gln-Cys-Ala-Ala-Leu-Trp-Leu-Gln-Cys-Ala-Ser-Gly-Gly-Thr-Ile-Gly-{Cys(D-glucopyranosyl)}-Gly-Gly-Gly-Ala-Val-Ala-Cys-Gln-Asn-Tyr-Arg-Gln-Phe-Cys-Arg (disulfide bridge: Cys7-Cys36, Cys14-Cys29)
-
Sequence Shortening
GLGKAQCAALWLQCASGGTIG-{Cys(D-glucopyranosyl)}-GGGAVACQNYRQFCR (disulfide bridge: Cys7-Cys36, Cys14-Cys29)
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
PCNA Immunodetection Proliferation Assay
PCNA immunodetection measures proliferative activity by detecting proliferating cell nuclear antigen, a nuclear protein associated with DNA polymerase δ function and DNA replication. The assay readout is the proportion of PCNA-positive nuclei among total counted cells, but PCNA labeling is not identical to BrdU labeling because PCNA can mark late G1/early S-associated replication competence and may persist beyond active DNA synthesis depending on fixation and extraction conditions.
Purity & Documentation
References
[1]. Wang S, et al., Use of the Antimicrobial Peptide Sublancin with Combined Antibacterial and Immunomodulatory Activities To Protect against Methicillin-Resistant Staphylococcus aureus Infection in Mice. J Agric Food Chem. 2017 Oct 4;65(39):8595-8605. [Content Brief]
[2]. Wu C, et al., Investigations into the Mechanism of Action of Sublancin. ACS Infect Dis. 2019 Mar 8;5(3):454-459. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)